MajorCentrally acting sympathomimetics×Class Ia antiarrhythmic (sodium channel blocker with intermediate kinetics)
Updated · Methodology
Mechanism
The liver breaks down atomoxetine mainly through the enzyme CYP2D6 (atomoxetine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Therapeutic levels of quinidine inhibit this enzyme so that people with normal CYP2D6 handle its substrates like poor metabolizers (quinidine label, US Food and Drug Administration, FDA). The atomoxetine FDA label lists quinidine among strong CYP2D6 inhibitors, which raise atomoxetine concentrations to the levels of poor metabolizers. In poor metabolizers, the atomoxetine area under the curve is about 10 times and the peak concentration about 5 times higher than in people with normal enzyme activity (atomoxetine FDA label and SmPC). Quinidine itself prolongs the QT interval in a dose-related way and can cause torsade de pointes (quinidine FDA label). QT prolongation is among the adverse reactions of atomoxetine. In a dedicated study, the corrected QT interval (QTc) rose slightly as atomoxetine concentration increased (atomoxetine SmPC, AEMPS). The atomoxetine SmPC names class IA antiarrhythmics and CYP2D6 inhibitors among combinations with a risk of QT prolongation, and quinidine belongs to both groups (atomoxetine SmPC, AEMPS).
Symptoms
With a strong CYP2D6 inhibitor such as quinidine, atomoxetine exposure is similar to that of poor metabolizers, people whose CYP2D6 does not work (atomoxetine label, US Food and Drug Administration, FDA). Compared with adult extensive metabolizers, whose CYP2D6 works normally, adult poor metabolizers had dry mouth in 34.5% versus 17.4%, insomnia in 19.2% versus 11.3%, erectile dysfunction in 20.9% versus 8.9% and urinary retention in 5.9% versus 1.2%. In children, decreased appetite, insomnia, tremor and fainting were also more common in poor metabolizers (atomoxetine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Heart rate rose more in adult poor metabolizers than in other metabolizer types, on average by 11 versus 7.5 beats per minute (atomoxetine FDA label). QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). Torsade de pointes causes palpitations, dizziness and fainting. With quinidine, its risk is higher with a slow heart rate, low potassium, magnesium or calcium, and high quinidine levels (quinidine FDA label).
Management
The US Food and Drug Administration (FDA) atomoxetine label lists quinidine as a strong inhibitor of the enzyme CYP2D6. With it, start atomoxetine at 0.5 mg/kg per day in children and adolescents up to 70 kg and at 40 mg per day in heavier patients and adults (atomoxetine FDA label). Raise the dose to the usual target only after 4 weeks, if symptoms of attention deficit hyperactivity disorder (ADHD) have not improved and the starting dose is well tolerated (atomoxetine FDA label). The atomoxetine summary of product characteristics (SmPC) from the Spanish Agency of Medicines and Medical Devices (AEMPS) allows a slower titration and a lower final dose. If quinidine is started or stopped after the atomoxetine dose has been set, reassess response and tolerability (atomoxetine SmPC, AEMPS). Use atomoxetine with caution in congenital or acquired QT prolongation (atomoxetine SmPC, AEMPS). Its SmPC names class IA antiarrhythmics and CYP2D6 inhibitors among combinations with a risk of QT prolongation. Use quinidine with caution together with any drug metabolized by CYP2D6 (quinidine FDA label). Use quinidine with extreme care in congenital long QT syndrome, a history of torsade de pointes or marked QTc prolongation on quinidine or similar drugs (quinidine FDA label). The combination product of dextromethorphan and quinidine is contraindicated with drugs that both prolong the QT interval and are metabolized by CYP2D6 (dextromethorphan and quinidine FDA label). Measure pulse and blood pressure before starting atomoxetine, after each dose change and at least every 6 months (atomoxetine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- DailyMed: Quinidine: FDA prescribing information, Drug Interactions section (DailyMed) (2024)
- FDA: Quinidine Sulfate Tablets USP (quinidine sulfate) prescribing information (2023)– FDA, DailyMed setid b0d6341b-d880-4f0b-8844-bc788c03004a (Epic Pharma), revisión 11/2023, secciones Clinical Pharmacology, Warnings, Precautions (Drug Interactions) y Overdosage
- FDA: STRATTERA (atomoxetine) prescribing information (2026)– FDA, DailyMed setid 309de576-c318-404a-bc15-660c2b1876fb (Eli Lilly), revisión 06/2026 (versión 69), secciones 2.5, 6.2, 7, 8.7, 12.2 y 12.3
- AEMPS: Ficha técnica: Atomoxetina (nº registro 82446), sección 4.5 (2026)– AEMPS, CIMA, nº registro 82446 (Atomoxetina Cinfa 80 mg), revisión 09/2026, secciones 4.4, 4.5, 4.8, 5.1 y 5.2
- FDA: Atomoxetine capsules (American Health Packaging) prescribing information (2026)– FDA, DailyMed setid 10d36b32-0202-4c03-8a1a-cd5d53f231e7 (American Health Packaging), revisión 06/2026 (versión 8), secciones 2.5 y 7.2